|
FDA Panel Recommends Approval for Onyx’s Multiple Myeloma Drug, Votes Down Sanofi VTE Drug
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 11–0 with one abstention to recommend approval for Onyx Pharmaceuticals’ Kyprolis for patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives